AbbVie’s New Hepatitis C Treatment Won’t Cure Patient Access Issue

I-MAK co-director and co-founder Priti Krishtel gives her thoughts on AbbVie’s Mavyret— the latest hepatitis C treatment— sharing her concerns about pricing and access.